ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
Fermenta Biotech reported H1FY27 consolidated revenue of Rs. 261.9 Crore, a 7% YoY decline. Profit after tax fell 52% to Rs. 18.9 Crore, impacted by lower animal nutrition pricing.
Fermenta Biotech Limited's board has approved the closure of its inactive wholly-owned subsidiary, Fermenta Biotech (UK) Limited. The move aims to reorganize corporate structure and reduce compliance costs following the UK's exit from the EU.
Fermenta Biotech Ltd reported revenue from operations of ₹132.7 Cr (+1.9% YoY) and net profit of ₹9.4 Cr (-47.8% YoY) for Q2 FY27.
Fermenta Biotech schedules a board meeting on November 5, 2026 to approve unaudited quarterly and half-year results. The trading window stays closed until 48 hours after results.
Fermenta Biotech Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Fermenta Biotech Limited promoter Preeti Thakkar sold 11,65,938 equity shares (3.96%) in the open market. Her shareholding decreased from 7.61% to 3.65% following the transaction.
Fermenta Biotech Ltd promoter Preeti Thakkar sold 11,65,938 equity shares via open market sale. The transaction valued at ₹55.34 Crore reduced her stake from 7.61% to 3.65%.
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
Fermenta Biotech Limited received a credit rating upgrade from CARE Ratings. Long-term bank facilities were raised to 'CARE BBB+; Stable' and short-term to 'CARE A2'.
Fermenta Biotech Limited has re-appointed Ms. Rajeshwari Datla as a Non-Executive Non-Independent Director of the company, effective August 11, 2026.
Fermenta Biotech held its AGM and secured shareholder approval for resolutions including financial statements, dividend declaration, and director appointments. All seven resolutions were passed successfully.
Q1FY27 revenue flat sequentially at INR 126.2 crore. Human nutrition volume grew 18% QoQ, offsetting animal nutrition weakness. EBITDA stood at INR 22.4 crore (17.7% margin).
Fermenta Biotech reported Q1FY27 consolidated revenue of ₹126.2 crore, down 13% YoY. Net profit for the period stood at ₹9.5 crore amid a 40% fall in animal nutrition realisations.
Fermenta Biotech Ltd reported revenue from operations of ₹121.8 Cr (-10.6% YoY) and net profit of ₹9.5 Cr (-56.0% YoY) for Q1 FY27.
Fermenta Biotech Limited has scheduled a board meeting on August 11, 2026, to consider and approve the standalone and consolidated unaudited financial results.
Fermenta Biotech Limited is now listed and admitted to dealings on the National Stock Exchange of India (NSE) effective from August 04, 2026.
The company submitted its quarterly shareholding pattern for the period ending June 30, 2026, as required by SEBI regulations.
Fermenta Biotech has scheduled its 74th Annual General Meeting for August 11, 2026. Agenda items include dividend declaration and approval for a Rs. 100 Crore related party transaction.
Fermenta Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Fermenta Biotech Limited has issued the notice for its 74th Annual General Meeting, scheduled to be held on August 11, 2026.
Fermenta Biotech Limited has filed its Annual Report for the financial year 2025-26. The company also announced its 74th Annual General Meeting scheduled for August 11, 2026.
Fermenta Biotech's subsidiary FESPL will issue equity shares to Aasava Management Services, diluting Fermenta's stake to 91.76%. FESPL thus ceases to be a wholly-owned subsidiary.
Fermenta Biotech clarified to BSE that recent share price movements are market-driven. The company confirmed no undisclosed material information or impending announcements exist.
Fermenta Biotech received FSSAI approval for its plant-based Vitamin D3 product. This regulatory greenlight supports its 'Make in India' initiative and nutrition self-reliance.
Fermenta Biotech Limited was ranked 7th nationwide among Great Place To Work’s Top 50 Mid-size Workplaces for 2026. The accolade highlights its strong employee‑first culture.
Fermenta Biotech Ltd applied to NSE for listing and trading of its equity shares. This move aims to enhance liquidity and investor access.
Fermenta Biotech delivered core revenue growth of 27% YoY in FY26, driven by Vitamin D3 segments, despite headline declines from a high real-estate base in FY25.
Fermenta Biotech reported ₹547.8 Crore FY26 consolidated revenue, up 14% YoY. Strong Vitamin D3 growth drove a 44% rise in EBITDA excluding real estate.